Syros Pharmaceuticals, A Leader In The Development Of Medicines That Control The Expression Of Genes, Today Announced That The U.S. Food And Drug Administration (Fda) Has Granted Orphan Drug Designation (Odd) To Tamibarotene For The Treatment Of Myelodysplastic Syndrome (Mds). Tamibarotene, An Oral First-In-Class Selective Retinoic Acid Receptor Alpha (Rar?) Agonist, Is Currently Being Evaluated In Combination With Azacitidine In The Select-Mds-1 Phase 3 Trial For Rara-Positive Patients With Newly Diagnosed Higher-Risk Mds (Hr-Mds).
